Immunotech Biopharm Ltd, a cellular immunotherapy biopharmaceutical company, focuses on the research, development, and commercialization of T cell immunotherapy products for the treatment of cancers in the People's Republic of China. The company's core product is EAL, a multi-target cellular immunotherapy product that has completed Phase III clinical trials for the prevention of postsurgical recurrence of liver cancer. It also develops CAR-T-19 injection product for B-cell acute lymphoblastic leukaemia that is in Phase II/III clinical trial; 6B11-OCIK injection that is in Phase I clinical trial for ovarian cancer; RC19D2 for relapsed and refractory diffuse large B-cell lymphoma that is in Phase I clinical trial; and TCR-T cell series products to treat solid tumors. In addition, the company develops pre-clinical products, such as aT19 to treat hematologic malignancies; YT003 and YT008 for post transplantation infections; YT007 for solid tumors; and VAC-aT19 for hematologic malignancies. Immunotech Biopharm Ltd was founded in 2006 and is headquartered in Beijing, the People's Republic of China. Address: Guosheng Technology Park, Beijing, China